

Checkmate 025

OS* 25 vs 19.6 mo HR .7
p+0.0018

ORR confirmed 21.5 v 3.9% >0.001

Duration of Response 23 vs 13.7 mo

Med time to response 3.0 vs 3.7 mo

Motzer NEJM 2015

Nivolumab vs everolimus

AXIS Inlyta (axitinib) vs Sorafanib

PFS* 6.7 vs 4.7 mo HR .665 p>0.0001

ORR 19.4 vs 9.4% HR.74

OS 20.1 vs 19.2 mo HR.97 p=.37

AXIS axitinib vs sorafanib Ph 3 Motzer/Rini
Lnacet Onc 2013

n=723 35% prior sunitinib, 35% cytokine, 8%
bev, 3% temsirolimus

Sunitinib refractory PFS 4.8 vs 3.4 mo HR.74

Cytokine refractory PFS 12.1 vs 6.5mo

DC due to AE's 4%

Ph 2 cytokine refractory 5 yr survival 20.6%
with 5.9 yr FU

METEOR

PFS* 7.4 vs 3.8 mo HR 0.58 p>0.0001

ORR 21 vs 5% p> 0.001

OS 21.4 vs 16.5 mo HR.66 p=0.0003

Choueiri NEJM 2015

n=658 Cabozantinib 60mg vs everolimus 10mg
69% had only 1 line of previous therapy

MSKCC 46% favorable, 42% intermediate, 13%
poor

Confirmed ORR (PR only) 17 vs 3% p>0.0001

Lenvima+Everolimus

PFS* 14.6 vs 5.5 mo HR.37

mOS 25.5 vs 15.4 mo HR.67

ORR 19 vs 3% p<0.001

ASCO 2015

n=153

major toxicity Diarrhea, fatigue, renal failure,
HTN,

89% dose reduction, 29% DC

Keynote

Os No met Who cated

oD Ghj Happy

Bevacizumab vs placebo

PFS* 10mg HR 2.55 p<0.001

PFS 3 mg HR 1.26 p=0.053

bevacizumab vs Placebo NEJM 2003 Yang
bev 3 or 10mg

NCCN Cat 2B after TKI



By Cheryllynn

cheatography.com/cheryllynn/

Not published yet.

Last updated 24th May, 2017.

Page 1 of 1.

Sponsored by **CrosswordCheats.com**

Learn to solve cryptic crosswords!

<http://crosswordcheats.com>